Isotretinoin Dosing for Acne

Dosing Strategy

The American Academy of Dermatology recommends starting isotretinoin at 0.5 mg/kg/day for the first month, then increasing to 1.0 mg/kg/day thereafter as tolerated, targeting a cumulative dose of 120-150 mg/kg to minimize relapse rates, with high-strength evidence supporting this approach 1, 2
Initial dose of 0.5 mg/kg/day for the first month is recommended for severe acne, as tolerated, to achieve optimal efficacy and minimize side effects 1, 2
Maintenance dose of 1.0 mg/kg/day after month one is recommended for severe acne, as tolerated, to achieve optimal efficacy and minimize side effects 1, 2
Target cumulative dose of 120-150 mg/kg provides optimal balance between efficacy and relapse prevention for severe acne, with moderate-strength evidence supporting this approach 1, 3

For treatment-resistant or quick-relapsing moderate acne, the American Academy of Dermatology recommends using low-dose isotretinoin at 0.25-0.4 mg/kg/day, which provides comparable efficacy to conventional dosing with fewer side effects and equal relapse rates, with moderate-strength evidence supporting this approach 1, 3
Low-dose isotretinoin at 0.25-0.4 mg/kg/day is recommended for moderate acne, with significantly reduced side effects compared to higher doses while maintaining efficacy, and equal relapse rates compared to conventional dosing regimens 1, 3

Isotretinoin must be taken with meals in two divided daily doses to ensure adequate absorption, as taking it without food significantly decreases bioavailability, with high-strength evidence supporting this approach 3
Taking isotretinoin with food is crucial to optimize absorption due to its high lipophilicity, with moderate-strength evidence supporting this approach 3

For acne fulminans or extremely severe presentations, starting at even lower doses than 0.5 mg/kg/day may be necessary, with low-strength evidence supporting this approach 1, 2
Concomitant oral corticosteroids may be needed to prevent isotretinoin-induced flares in extremely severe cases, with low-strength evidence supporting this approach 2

Intermittent dosing is not recommended as it is associated with significantly higher relapse rates compared to continuous daily dosing, with high-strength evidence supporting this approach 1, 3

The American Academy of Dermatology recommends using continuous daily dosing rather than intermittent dosing, as daily dosing produces greater reductions in inflammatory lesions (MD 3.87) and non-inflammatory lesions (MD 4.53) compared to intermittent dosing at 24 weeks 4
The American Academy of Dermatology suggests that intermittent dosing is associated with higher relapse rates despite lower withdrawal rates due to adverse effects 4
Both standard isotretinoin and lidose-isotretinoin may be used, as they show non-inferiority in efficacy, with 76.9% vs 81.0% achieving ≥90% reduction in total lesions at 20 weeks with no significant difference in adverse effects 4

The American Academy of Dermatology recommends screening for depression, anxiety, and suicidal ideation at baseline and throughout treatment, particularly in adolescents aged 12-18 years, using validated instruments like the Patient Health Questionnaire-2 and PHQ-9 4